AM-630

AM-630
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name 1-[2-(Morpholin-4-yl)ethyl]-2-methyl-3-(4-methoxybenzoyl)-6-iodoindole;
JSmol)	Interactive image;
	SMILES C4COCCN4CCn(c1C)c2cc(I)ccc2c1C(=O)c3ccc(OC)cc3;
	InChI InChI=1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3 ; Key:JHOTYHDSLIUKCJ-UHFFFAOYSA-N ;
	(what is this?) (verify)

AM-630 (6-Iodopravadoline) is a drug that acts as a potent and selective inverse agonist for the cannabinoid receptor CB₂, with a K_i of 32.1 nM at CB₂ and 165x selectivity over CB₁, at which it acted as a weak partial agonist.^[1]^[2] It is used in the study of CB₂ mediated responses and has been used to investigate the possible role of CB₂ receptors in the brain.^[3]^[4] AM-630 is significant as one of the first indole derived cannabinoid ligands substituted on the 6-position of the indole ring, a position that has subsequently been found to be important in determining affinity and efficacy at both the CB₁ and CB₂ receptors, and has led to the development of many related derivatives.^[5]^[6]^[7]^[8]^[9]

References

v
t
e

Retrieved from "https://en.wikipedia.org/w/index.php?title=AM-630&oldid=1205101777"

[pmid10188977-1] PMID 10188977
.

[2] PMID 22921769
.

[pmid19616018-3] S2CID 207224823
.

[pmid19931854-4] S2CID 14222913
.

[5] PMID 7636873
.

[6] Hongfeng Deng. Design and synthesis of selective cannabinoid receptor ligands: Aminoalkylindole and other heterocyclic analogs. PhD Dissertation, University of Connecticut, 2000.

[pmid12161142-7] PMID 12161142
.

[8] PMID 18311894
.

[9] :10.1039/c0md00022a
.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

See also

References